A histopathological study of the effects of 6-month versus 12-month interferon α-2b therapy in chronic hepatitis C

Journal of Hepatology

Volumn 25, Issue 6, 1996, Pages 833-841

  Ziol, Marianne ^a   Van Nhieu, Jeanne Tran ^a   Roudot Thoraval, Françoise ^a   Métreau, Jean Michel ^a   Deugnier, Yves ^a   Dhumeaux, Daniel ^a   Zafrani, Elie Serge ^a  

^a HENRI MONDOR HOSPITAL   (France)

Author keywords

Chronic hepatitis C; Fibrosis; Hepatitis C virus; Histological score; Interferon therapy.

Indexed keywords

ALPHA2B INTERFERON;

ARTICLE; CHRONIC HEPATITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HEPATITIS C; HEPATITIS C VIRUS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LIVER FIBROSIS; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; VIRUS HEPATITIS;

EID: 0030445466     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8278(96)80286-8     Document Type: Article

References (31)

1. 1. Giral P, Serfaty L, Loria A, Poupon R. Hepatite C. Rev Med Intern 1994; 15: 487-93.
2. 2. Tsukuma H, Hiyama T, Tanaka S, Nakao M, Yabunchi T, Kitamira T, Nakanishi K, Fujimoto I, Inoue A, Yamasaki H, Kawashima T. Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N Engl J Med 1993; 328: 1797-801.
3. 3. Pawlotsky JM, Marcellin P, Trepo C, Dhumeaux D. Traitement des hepatites virales C. Gastroenterol Clin Biol 1994; 18: 362-73.
4. 4. Hoofnagle JH. Therapy of chronic hepatitis B and C. In: Miguet JP, Dhumeaux D, eds. Progress in Hepatology 93. Paris: John Libbey Eurotext, 1993: 89-97.
5. 5. Metreau JM and the French Group for the study of NANB/C chronic hepatitis treatment. Results of long-term interferon treatment in non-A, non-B/C chronic active hepatitis. Gut 1993; suppl: S112-S113.
6. 6. Jouet P, Roudot-Thoraval F, Dhumeaux D, Metreau JM, and the French Group for the Study of NANB/C Chronic Hepatitis Treatment. Comparative efficacy of Interferon alpha in cirrhotic and noncirrhotic patients with non-A non-B, C hepatitis. Gastroenterology 1994; 106: 686-90.
7. 7. Milella M, Santantonio M, Monno L, Pastore G. Comparison of short vs long term treatment with recombinant alpha interferon in chronic hepatitis C (Abstract). In: Abstracts of the 1993 International Symposium on Viral Hepatitis and Liver Disease, Tokyo 1993: 245.
8. 8. Chemello L, Pontisso P, Rose KA, Simmonds P, Bonetti P, Cavalletto L. The long-term response (LTR) to interferon alpha-2a(IFN-2a) in chronic hepatitis C is influenced by dose and duration of treatment and by the HCV serotype (abstract). J Hepatol 1993; 18(suppl 1): S10-S11.
9. 9. Camps J, Castilla A, Ruiz J, Civeira MP, Prieto J. Randomised trial of lymphoblastoid α-interferon in chronic hepatitis C. J Hepatol 1993; 17: 390-6.
10. 10. Reichard O, Glaumann H, Norkrans G, Wejstal R, Fryden A, Schvarcz R, Weiland O. Histological outcome in patients with chronic hepatitis C given a 60-week interferon alfa-2b treatment course. Liver 1994; 14: 169-74.
11. 11. Causse X, Godinot H, Chevallier M, Chossegros P, Zoulim F, Ouzan D, Heyraud JP, Fontanges T, Albrecht J, Meschievitz C, Trepo C. Comparison of 1 or 3 MU of interferon alfa2b and placebo in patients with chronic non-A, non-B hepatitis. Gastroenterology 1991: 101: 497-502.
12. 12. Marcellin P, Pouteau M, Duchatelle V, Degott C, Degos F, Boyer N, Erlinger S, Benhamou JP. Post-treatment histologic outcome in patients with chronic hepatitis C treated with recombinant alpha interferon. In: AASLD Abstracts. Hepatology 1993; 18: 243A.
13. 13. The French METAVIR Cooperative Study Group. Intra- and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. Hepatology 1994; 20: 15-20.
14. 14. Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, Kiernan TW, Wollman J. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981; 1: 431-5.
15. 15. Czaja AJ, Carpenter HA. Sensitivity, specificity and predictability of biopsy interpretations in chronic hepatitis. Gastroenterology 1993; 105: 1824-32.
16. 16. Bach N, Thung SN, Schaffner F. The histological features of chronic hepatitis C and autoimmune chronic hepatitis: a comparative analysis. Hepatology 1992; 15: 572-7.
17. 17. Lefkowitch JH, Schiff ER, Davis GL, Perillo RP, Lindsay K, Bodenheimer HC, Balart LA, Ortego TJ, Payne J, Dienstag JL, Gibas A, Jacobson IM, Tamburro CH, Carey W, O'Brien C, Sampliner R, Van Thiel DH, Feit D, Albrecht J, Meschievitz C, Sabghvi B, Vaughan RD. Pathological diagnosis of chronic hepatitis C. A multicenter comparative study with chronic hepatitis B. Gastroenterology 1993; 104: 595-603.
18. 18. Scheuer PJ, Ashrafzadeh P, Sherlock S, Brown D, Dusheiko GM. The pathology of hepatitis C. Hepatology 1992; 15: 567-71.
19. 19. Friedman SL. The cellular basis of hepatic fibrosis. Mechanisms and treatment strategies. N Engl J Med 1993; 328: 1828-35.
20. 20. Lau JYN, Davis GL, Kniffen J, Qian KP, Urdea MS, Chan CS, Mizokami M, Neuwald PD, Wilber CW. Significance of serum hepatitis C virus RNA levels on chronic hepatitis C. Lancet 1993: 341: 1501-4.
21. 21. Krawczynski K, Beach MJ, Bradley DW. Hepatitis C virus antigen in hepatocytes: immunomorphologic detection and identification. Gastroenterology 1992; 103: 622-9.
22. 22. Tran Van Nhieu J, Roudot-Thoraval F, Pawlotsky JM, Pellet C, Dhumeaux D, Zafrani ES. Relationship between genotypes of C virus and histologic liver lesions in chronic hepatitis C infection. In: AASLD Abstracts. Hepatology 1994; 20: 247A.
23. 23. David E, Puci A, Palladin D, Saracco G, Garello E, Pintus C, Roca G, Chiandussi L, Solinas A, Mollo F, Rizetto M, Mazzuco G, Verme G. Histologic changes in liver biopsy specimens produced by recombinant interferon α-2b therapy for chronic non-A, non-B viral hepatitis. Am J Clin Pathol 1992; 98: 397-401.
24. 24. Davis GL, Balart LA, Schiff ER, Lindsay K, Bodenheimer HC, Perrillo RP, Garey W, Jacobson IM, Payne J, Dienstag JL, VanThiel DH, Tamburro C, Lefkowitch J, Albrecht J, Meschievitz C, Ortego TJ, Gibas A, and The Hepatitis International Therapy Group. Treatment of chronic hepatitis C recombinant interferon alfa. N Engl J Med 1989; 321: 1501-6.
25. 25. Di Bisceglie AM, Martin P, Kassianides C, Lisker-Melman M, Murray L, Waggoner J, Goodman Z, Banks SM, Hoofnagle JH. Recombinant interferon alfa therapy for chronic hepatitis C. N Engl J Med 1989; 321: 1506-10.
26. 26. Omata M, Ito Y, Yokosuka O, Imazeki F, Tagawa M, Takano S, Hosoda K, Tada M, Ohto M, Ito K, Okuda K. Randomized, double-blind, placebo-controlled trial of eight-week course of recombinant α-interferon for chronic non-A, non-B hepatitis. Dig Dis Sci 1991; 36: 1217-22.
27. 2b therapy reduces liver fibrosis in chronic non-A, non-B hepatitis. A quantitative histological evaluation. Hepatology 1993; 18: 1344-9.
28. 28. Mallat A, Preaux AM, Blazejewski S, Rosenbaum J, Dhumeaux D, Mavier P. Interferon alpha and gamma inhibit proliferation and collagen synthesis of human Ito cells in culture. Hepatology 1995; 21: 1003-10.
29. 29. Castilla A, Prieto J, Fausto N. Transforming growth factors ß1 and α in chronic liver disease. N Engl J Med 1991; 324: 933-40.
30. 30. Pagliario L, Craxi A, Camaa C, Tine F, Di Marco V, Lo Iacono O, Almaso P. Interferon-α for chronic hepatitis C: an analysis of pretreatment clinical predictors of response. Hepatology 1994; 19: 820-28.
31. 31. Schvarez R, Glauman H, Weiland O, Norkrans G, Wejstal R, Fryden A. Interferon alpha2b treatment of chronic posttransfusion non-A, non-B/C hepatitis: long-term outcome and effect of increased interferon doses in non-responders. Scand J Infect Dis 1991; 23: 413-20.